Long noncoding RNA DANCR aggravates retinoblastoma through miR ‐34c and miR‐613 by targeting MMP‐9

Journal of Cellular Physiology, EarlyView.
Source: Journal of Cellular Physiology - Category: Cytology Authors: Source Type: research

Related Links:

Conclusions: Mutations in the RB1 gene in Vietnamese patients were heterogeneous and highly prevalent with pathogenic truncated mutations. With advancement in therapeutics, early detection of RB is important for eye salvation. PMID: 30996590 [PubMed - in process]
Source: Molecular Vision - Category: Molecular Biology Tags: Mol Vis Source Type: research
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human diseases. FI...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
CONCLUSIONS: Therefore, NKILA inhibits retinoblastoma possibly by downregulating XIST, but the causality has not been fully validated. PMID: 30995132 [PubMed - as supplied by publisher]
Source: Current Eye Research - Category: Opthalmology Authors: Tags: Curr Eye Res Source Type: research
Conclusion: Our data supports that never/ever smoker patients with small-cell lung cancer have better prognosis compared to their smoker counterparts. Further, patients with never/ever smoking history who present with small-cell lung cancer have a different mutation profile compared with smokers, including a high frequency of EGFR, MET, and SMAD4 mutations. Further studies are required to assess whether the differential mutation profile is a consequence of a diverse pathological mechanism for disease onset. Introduction Lung cancer is the most common neoplasia worldwide. Aside from the high incidence, lung cancer a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Siriluck Ponsuksili1, Nares Trakooljul1, Frieder Hadlich1, Karen Methling2, Michael Lalk2, Eduard Murani1 and Klaus Wimmers1,3* 1Leibniz Institute for Farm Animal Biology (FBN), Institute for Genome Biology, Functional Genome Analysis Research Unit, Dummerstorf, Germany 2Institute for Biochemistry – Metabolomics, University of Greifswald, Greifswald, Germany 3Faculty of Agricultural and Environmental Sciences, University of Rostock, Rostock, Germany Given the central metabolic role of the liver, hepatic metabolites and transcripts reflect the organismal physiological state. Biochemical-clinical plasma bio...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Gracie Corrigan, from Oregon, was diagnosed with the rare eye cancer retinoblastoma when doctors found 10 tumours around her right eye after her mother noticed it looked odd in a photo.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Swetha Rajasekaran1,2,3†, Lakshmi Dhevi Nagarajha Selvan4†, Kathleen Dotts1,2,3†, Ranjith Kumar4, Pukhraj Rishi5, Vikas Khetan5, Madhoolika Bisht1,2,3, Karthikeyan Sivaraman6, Subrmanian Krishnakumar7, Debashis Sahoo8, Moray J. Campbell9, Sailaja V. Elchuri4* and Wayne O. Miles1,2,3* 1Department of Molecular Genetics, The Ohio State University, Columbus, OH, United States2The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States3Center for RNA Biology, The Ohio State University, Columbus, OH, United States4Department of Nanobiotechnology, Vision Research Foundation, Sank...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions In the new era of targeted therapy, treatment options are increasingly based on the precise molecular and genetic profiling of tumor cells (58). Currently, the main challenge for further novel drug development in targeted therapy is the clarification of specific molecular mechanisms underlying the varied forms of tumors in clinic. It has been acknowledged that cancer is caused by a set of driver mutations. In this regard, it is of great significance to: (1) identify and validate key mutant genes and proteins in cancers as new targets; (2) identify patients most likely and unlikely to benefit from certain targe...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
.
Source: Pediatric Hematology and Oncology - Category: Pediatrics Authors: Source Type: research
More News: Cytology | Eye Cancers | Physiology | Retinoblastoma